{
    "organizations": [],
    "uuid": "36f5484c1924797634cc4188d98aba064e332a7a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oryzon-genomics-gets-approval-in-s/brief-oryzon-genomics-gets-approval-in-spain-to-start-phase-iia-clinical-trial-in-alzheimers-disease-with-ory-2001-idUSFWN1RG0WV",
    "ord_in_thread": 0,
    "title": "BRIEF-Oryzon Genomics Gets Approval In Spain To Start Phase IIa Clinical Trial In Alzheimer's Disease With ORY-2001",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Oryzon Genomics SA:\n* GETS APPROVAL TO START ETHERAL: A PHASE IIA CLINICAL TRIAL IN ALZHEIMERâ€™S DISEASE WITH ORY-2001\n* EXPECTS TO START PATIENT ENROLLMENT THIS QUARTER * FIRST APPROVAL RECEIVED FROM AEMPS IN SPAIN, APPROVALS FROM OTHER EUROPEAN AGENCIES EXPECTED SOON\n* AIMS TO LAUNCH A TWIN STUDY IN THE US WITH A NUMBER OF ADDITIONAL PATIENTS Source text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-04T14:20:00.000+03:00",
    "crawled": "2018-04-05T17:10:03.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "oryzon",
        "genomics",
        "sa",
        "get",
        "approval",
        "start",
        "etheral",
        "phase",
        "iia",
        "clinical",
        "trial",
        "alzheimer",
        "disease",
        "expects",
        "start",
        "patient",
        "enrollment",
        "quarter",
        "first",
        "approval",
        "received",
        "aemps",
        "spain",
        "approval",
        "european",
        "agency",
        "expected",
        "soon",
        "aim",
        "launch",
        "twin",
        "study",
        "u",
        "number",
        "additional",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}